Advertisement
U.S. markets open in 49 minutes
  • S&P Futures

    5,309.25
    +1.00 (+0.02%)
     
  • Dow Futures

    40,164.00
    +20.00 (+0.05%)
     
  • Nasdaq Futures

    18,512.00
    +8.25 (+0.04%)
     
  • Russell 2000 Futures

    2,140.90
    +2.50 (+0.12%)
     
  • Crude Oil

    82.65
    +1.30 (+1.60%)
     
  • Gold

    2,230.20
    +17.50 (+0.79%)
     
  • Silver

    24.72
    -0.04 (-0.15%)
     
  • EUR/USD

    1.0796
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.2280
    +0.0320 (+0.76%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2627
    -0.0011 (-0.09%)
     
  • USD/JPY

    151.2800
    +0.0340 (+0.02%)
     
  • Bitcoin USD

    70,438.17
    +367.49 (+0.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,949.42
    +17.44 (+0.22%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Celgene halts Revlimid ORIGIN trial due to deaths

Celgene announced that after consultation with the FDA, it will discontinue treatment with Revlimid in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries. An imbalance was observed in the number of deaths in patients treated with lenalidomide versus patients treated with chlorambucil. The FDA placed the ORIGIN study on clinical hold on July 12, with the discontinuation of lenalidomide treatment. All clinical investigators in ongoing chronic lymphocytic leukemia studies using lenalidomide will be officially advised of this action and instructed to inform their patients accordingly, Celgene said. Revlimid is not approved as a treatment for patients with chronic lymphocytic leukemia. Based on an imbalance in deaths, specifically 34 deaths out of 210 patients in the lenalidomide arm compared to 18 deaths out of 211 patients in the chlorambucil arm, FDA placed the study on clinical hold. No specific causality for this imbalance has been identified to date. All other Celgene-sponsored chronic lymphocytic leukemia clinical trials with lenalidomide are continuing in accordance with their respective protocols, the company added.

Advertisement